A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults*
Top Cited Papers
- 1 August 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 43 (8), 1622-1629
- https://doi.org/10.1097/ccm.0000000000001004
Abstract
To determine whether regional anticoagulation of continuous renal replacement therapy circuits using citrate and calcium prolongs circuit life and/or affects circulating cytokine levels compared with regional anticoagulation using heparin and protamine.Multicenter, parallel group randomized controlled trial.Seven ICUs in Australia and New Zealand.Critically ill adults requiring continuous renal replacement therapy.Patients were randomized to receive one of two methods of regional circuit anticoagulation: citrate and calcium or heparin and protamine.The primary outcome was functional circuit life measured in hours, assessed using repeated events survival analysis. In addition, we measured changes in interleukin-6, interleukin-8, and interleukin-10 blood levels. We randomized 212 subjects who were treated with 857 continuous renal replacement therapy circuits (median 2 circuits per patient [interquartile range, 1-6], 390 in citrate group vs 467 in heparin group). The groups were well matched for baseline characteristics. Patients receiving regional continuous renal replacement therapy anticoagulation with heparin and protamine were more likely to experience circuit clotting than those receiving citrate and calcium (hazard ratio, 2.03 [1.36-3.03]; p < 0.0005; 857 circuits). The median lifespan of the first study circuit in each patient was 39.2 hours (95% CI, 32.1-48.0 hr) in the citrate and calcium group versus 22.8 hours (95% CI, 13.3-34.0 hr) in the heparin and protamine group (log rank p = 0.0037, 204 circuits). Circuit anticoagulation with citrate and calcium had similar effects on cytokine levels compared with heparin and protamine anticoagulation. There were more adverse events in the group assigned to heparin and protamine anticoagulation (11 vs 2; p = 0.011).Regional citrate and calcium anticoagulation prolongs continuous renal replacement therapy circuit life compared with regional heparin and protamine anticoagulation, does not affect cytokine levels, and is associated with fewer adverse events.This publication has 14 references indexed in Scilit:
- Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trialCritical Care, 2014
- Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guideBMJ, 2014
- Arterial Stiffness Depends on Serum Ionized Calcium Levels During Dialysis With Regional Citrate AnticoagulationArtificial Organs, 2013
- Regional Citrate Anticoagulation Reduces Polymorphonuclear Cell Degranulation in Critically Ill Patients Treated With Continuous Venovenous HemofiltrationTherapeutic Apheresis and Dialysis, 2011
- Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trialNephrology Dialysis Transplantation, 2010
- A Pilot Randomized Controlled Crossover Study Comparing Regional Heparinization to Regional Citrate Anticoagulation for Continuous Venovenous HemofiltrationThe International Journal of Artificial Organs, 2007
- Clinical review: Patency of the circuit in continuous renal replacement therapyCritical Care, 2007
- Repeated events survival models: the conditional frailty modelStatistics in Medicine, 2005
- Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patientsKidney International, 2005
- Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized studyIntensive Care Medicine, 2004